News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,203 Results
Type
Article (43756)
Company Profile (318)
Press Release (697116)
Multimedia
Podcasts (115)
Webinars (19)
Section
Business (210975)
Career Advice (2107)
Deals (36755)
Drug Delivery (123)
Drug Development (83404)
Employer Resources (176)
FDA (16814)
Job Trends (15499)
News (357315)
Policy (34124)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2610)
Accelerated approval (31)
Adcomms (26)
Allergies (143)
Alliances (51585)
ALS (171)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (318)
Approvals (17074)
Artificial intelligence (523)
Autoimmune disease (146)
Automation (37)
Bankruptcy (372)
Best Places to Work (11771)
BIOSECURE Act (21)
Biosimilars (193)
Biotechnology (188)
Bladder cancer (157)
Brain cancer (59)
Breast cancer (641)
Cancer (4826)
Cardiovascular disease (410)
Career advice (1786)
Career pathing (36)
CAR-T (279)
CDC (47)
Celiac Disease (2)
Cell therapy (742)
Cervical cancer (36)
Clinical research (71075)
Collaboration (1723)
Company closure (4)
Compensation (1147)
Complete response letters (60)
COVID-19 (2782)
CRISPR (93)
C-suite (837)
Cystic fibrosis (148)
Data (6185)
Decentralized trials (2)
Denatured (36)
Depression (133)
Diabetes (501)
Diagnostics (6755)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (249)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (227)
Earnings (91763)
Editorial (58)
Employer branding (21)
Employer resources (154)
Events (120119)
Executive appointments (984)
FDA (19923)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1462)
Gene editing (199)
Generative AI (44)
Gene therapy (602)
GLP-1 (1009)
Government (4794)
Grass and pollen (7)
Guidances (384)
Healthcare (19052)
HIV (55)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (256)
Immuno-oncology (54)
Indications (104)
Infectious disease (3041)
Inflammatory bowel disease (192)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (247)
Interviews (326)
IPO (16917)
IRA (56)
Job creations (4069)
Job search strategy (1498)
JPM (63)
Kidney cancer (15)
Labor market (83)
Layoffs (574)
Leadership (32)
Legal (8422)
Liver cancer (92)
Longevity (15)
Lung cancer (646)
Lymphoma (374)
Machine learning (43)
Management (60)
Manufacturing (805)
MASH (166)
Medical device (13839)
Medtech (13891)
Mergers & acquisitions (20897)
Metabolic disorders (1285)
Multiple sclerosis (155)
NASH (17)
Neurodegenerative disease (314)
Neuropsychiatric disorders (89)
Neuroscience (2914)
Neurotech (1)
NextGen: Class of 2026 (6645)
Non-profit (4556)
Now hiring (65)
Obesity (607)
Opinion (282)
Ovarian cancer (165)
Pain (213)
Pancreatic cancer (224)
Parkinson's disease (281)
Partnered (34)
Patents (494)
Patient recruitment (474)
Peanut (58)
People (60835)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22065)
Phase 2 (31250)
Phase 3 (23421)
Pipeline (5115)
Policy (294)
Postmarket research (2655)
Preclinical (9377)
Press Release (68)
Prostate cancer (236)
Psychedelics (49)
Radiopharmaceuticals (283)
Rare diseases (847)
Real estate (6306)
Recruiting (71)
Regulatory (25312)
Reports (51)
Research institute (2433)
Resumes & cover letters (360)
Rett syndrome (27)
RNA editing (17)
RSV (76)
Schizophrenia (154)
Series A (243)
Series B (187)
Service/supplier (11)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (160)
Sponsored (42)
Startups (3764)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (77)
Vaccines (1013)
Venture capital (88)
Weight loss (399)
Women's health (87)
Worklife (18)
Date
Last 7 days (600)
Last 30 days (2116)
Last 365 days (30209)
2026 (2852)
2025 (30680)
2024 (35769)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47399)
2018 (35771)
2017 (33137)
2016 (32663)
2015 (38616)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30488)
2010 (28497)
Location
Africa (801)
Alabama (83)
Alaska (7)
Arizona (312)
Arkansas (14)
Asia (42118)
Australia (6743)
California (11220)
Canada (3273)
China (1122)
Colorado (474)
Connecticut (471)
Delaware (336)
Europe (90242)
Florida (1667)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (868)
India (65)
Indiana (523)
Iowa (22)
Japan (429)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8080)
Michigan (322)
Minnesota (625)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2985)
New Mexico (29)
New York (2961)
North Carolina (1457)
North Dakota (8)
Northern California (5457)
Ohio (331)
Oklahoma (22)
Oregon (46)
Pennsylvania (2271)
Puerto Rico (22)
Rhode Island (47)
South America (1175)
South Carolina (66)
South Dakota (1)
Southern California (4367)
Tennessee (172)
Texas (1733)
United States (39890)
Utah (336)
Vermont (1)
Virginia (272)
Washington D.C. (81)
Washington State (923)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
741,203 Results for "vanda pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
February 5, 2026
·
1 min read
Press Releases
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
December 12, 2025
·
1 min read
Press Releases
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
December 1, 2025
·
4 min read
Press Releases
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
January 8, 2026
·
5 min read
Press Releases
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
November 5, 2025
·
1 min read
Press Releases
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
October 30, 2025
·
13 min read
Press Releases
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
December 30, 2025
·
9 min read
Complete response letters
Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
The DC-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for Hetlioz and promised to keep pushing for an approval.
January 8, 2026
·
2 min read
·
Dan Samorodnitsky
Regulatory
After Court Win, Vanda Asks Makary To Review ‘Unacceptable’ Approval of Rival Generics
Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting that FDA Commissioner Marty Makary revisit the decision.
August 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
November 18, 2025
·
7 min read
1 of 74,121
Next
